BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05677659 (Iluzanebart in Adult-Onset Leukoencephalopathy With Axonal Spheroids and…): BVCT ex-ante prediction vs. reported outcome

On 12 May 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 4 Jun 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05677659
Acronym
IGNITE
Drug Name
Iluzanebart (VGL101)
Drug MoA
TREM2 agonist
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Human Patients
20
Sponsor
Vigil Neuroscience
Phase
Phase 2

Prediction of , index 1262

Prospective Prediction
Prediction Index
1262
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
388 days in advance
Readout Data Interpretation
Iluzanebart failed to achieve statistically significant clinical benefit in primary efficacy endpoints
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Safety, Tolerability, and Proof-of-Concept Study of VGL101 in Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) (The Ignite Study)
Phase
Phase 2
Status
Terminated
Enrollment
20
Lead sponsor
Vigil Neuroscience, Inc.
Conditions
ALSP
Interventions
DRUG: VGL101
Design
Single group · None
Primary purpose
Treatment
Start
2022-12-14
Primary completion
2025-02-14
Completion
2025-06-04
Primary outcomes
  • Core Study Adverse Events (Through Week 52)
  • Long-Term Extension Adverse Events (Week 52 through Week 148)

NCT05677659 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials